AR128003A1 - PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS - Google Patents

PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS

Info

Publication number
AR128003A1
AR128003A1 ARP220103478A ARP220103478A AR128003A1 AR 128003 A1 AR128003 A1 AR 128003A1 AR P220103478 A ARP220103478 A AR P220103478A AR P220103478 A ARP220103478 A AR P220103478A AR 128003 A1 AR128003 A1 AR 128003A1
Authority
AR
Argentina
Prior art keywords
polypeptide
acid sequence
idua
iduronidase
enzymes
Prior art date
Application number
ARP220103478A
Other languages
English (en)
Spanish (es)
Inventor
Gowrisudha Adusumilli
Oliver Brayer Davis
Mihalis S Kariolis
Cathal S Mahon
Shrishti Tyagi
Kensuke Yamanokuchi
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of AR128003A1 publication Critical patent/AR128003A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP220103478A 2021-12-17 2022-12-16 PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS AR128003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163291283P 2021-12-17 2021-12-17

Publications (1)

Publication Number Publication Date
AR128003A1 true AR128003A1 (es) 2024-03-20

Family

ID=85175822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103478A AR128003A1 (es) 2021-12-17 2022-12-16 PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS

Country Status (12)

Country Link
US (1) US20250136963A1 (OSRAM)
EP (1) EP4448746A1 (OSRAM)
JP (1) JP2024546129A (OSRAM)
KR (1) KR20240119118A (OSRAM)
CN (1) CN118401660A (OSRAM)
AR (1) AR128003A1 (OSRAM)
AU (1) AU2022415476A1 (OSRAM)
CA (1) CA3241240A1 (OSRAM)
IL (1) IL313553A (OSRAM)
MX (1) MX2024007319A (OSRAM)
TW (1) TW202340459A (OSRAM)
WO (1) WO2023114485A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202542190A (zh) * 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180185495A1 (en) * 2014-11-10 2018-07-05 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
KR20250073514A (ko) * 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
JP7669113B2 (ja) 2017-02-17 2025-04-28 デナリ セラピューティクス インコーポレイテッド トランスフェリン受容体トランスジェニックモデル
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
EP3807322A1 (en) * 2018-06-18 2021-04-21 Denali Therapeutics Inc. Fusion proteins comprising progranulin
CN115698037A (zh) * 2020-02-07 2023-02-03 戴纳立制药公司 用于治疗亨特综合征的方法

Also Published As

Publication number Publication date
US20250136963A1 (en) 2025-05-01
KR20240119118A (ko) 2024-08-06
TW202340459A (zh) 2023-10-16
CN118401660A (zh) 2024-07-26
JP2024546129A (ja) 2024-12-17
WO2023114485A1 (en) 2023-06-22
IL313553A (en) 2024-08-01
MX2024007319A (es) 2024-07-22
CA3241240A1 (en) 2023-06-22
EP4448746A1 (en) 2024-10-23
AU2022415476A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
de Lencastre Novaes et al. Stability, purification, and applications of bromelain: A review
AR123788A1 (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
JP5620640B2 (ja) 改良されたボツリヌス毒素組成物
ES2592314T3 (es) Neurotoxinas clostridiales con persistencia modificada
JP2019194251A5 (OSRAM)
IL262976A (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
ES2632470T3 (es) Proteínas de fusión y métodos para tratar, prevenir o mejorar el dolor
Girdhar et al. Antimicrobial peptide-based strategies to overcome antimicrobial resistance
HRP20141125T1 (hr) Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
MX2024015050A (es) L-asparaginasa modificada
AR058567A1 (es) Formulaciones de proteinas estables
MX2012002216A (es) Nueva endolisina obpgplys.
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta
AR081680A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DEL a N-ACETIL GLUCOSAMINIDASA
ES2371785T3 (es) Utilización de al menos una neurotoxina botulínica para tratar el dolor causado por los tratamientos terapéuticos del virus del sida.
CO2023014723A2 (es) Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
ES2911075T3 (es) Constructos de administración para transcitosis y métodos relacionados
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
BRPI1014631A2 (pt) peptídeos e seus usos.
JP2021525711A5 (OSRAM)
MX2022008748A (es) Administración oral de péptidos.
WO2003082315A1 (fr) Remede contre l'hypermyotonie